«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年04期

页码:

337-341

栏目:

临床医学

出版日期:

2019-07-20

文章信息/Info

Title:

Correlation between the number of positive sentinel lymph nodes and non-sentinel lymph node metastasis in early breast cancer

文章编号:

1006-8147(2019)04-0337-05

作者:

王 雪; 陈丽璇; 孙娅惠; 张 斌

（天津医科大学肿瘤医院乳腺肿瘤一科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室，天津300060）

Author(s):

WANG Xue;  CHEN Li-xuan;  SUN Ya-hui;  ZHANG Bin

(The First Department of Breast Cancer, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer,Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China)

关键词:

乳腺癌; 前哨淋巴结转移; 腋窝淋巴结清扫; 非前哨淋巴结转移; ACOSOG Z0011

Keywords:

breast cancer;  sentinel lymph node metastasis;  axillary lymph node dissection;  non-sentinel lymph node;  ACOSOG Z0011

分类号:

R737.9

DOI:

-

文献标志码:

A

摘要:

目的：前哨淋巴结（SLN）的状态明显影响腋窝淋巴结清扫（ALND）。该研究的目的是分析前哨淋巴结阳性个数与早期乳腺癌非前哨淋巴结转移（NSLN）的相关性。方法：回顾性分析天津医科大学肿瘤医院2014年1月-2017年12月收治的符合Z0011试验纳入标准（cT1-2N0）的SLN阳性且行腋窝淋巴结清扫的早期浸润性乳腺癌，对与NSLN转移相关的变量进行单因素及多因素Logistic回归分析。结果：根据纳入和排除标准，495例患者纳入研究，174例（35.2%）发生NSLN转移；单因素分析显示SLN阳性个数≥ 3（P<0.000）、受体状态（P = 0.007）和淋巴血管侵犯（P =0.006）与NSLN转移相关；多因素分析显示SLN阳性个数≥ 3是NSLN转移的最重要的独立预测因子（OR=6.604；95 % CI3.451~12.638；P<0.000）。对于0、1、2或3个相关的危险因素的患者，NSLN转移率分别为16.4 %、23.1 %、39.1 %和60.7 %。结论：SLN阳性个数、受体状态和脉管浸润与NSLN转移相关。SLN阳性个数≥ 3是NSLN转移最重要的独立预测因素。当存在2或3个危险因素时，NSLN转移率高于ACOSOG Z0011试验的 27.3 %，强烈建议行ALND。

Abstract:

Objective: To perform the state of sentinel lymph nodes (SLN) affects whether axillary lymph node dissection (ALND) and to analyze the correlation between the number of positive sentinel lymph nodes and non-sentinel lymph node metastasis in early breast cancer. Methods：Data were extracted from the retrospective database of Tianjin Medical University Cancer Hospital from January 2014 to December 2017. Patients who met Z0011 trial inclusion criteria of cT1-2N0 invasive breast cancer in SLN-positive with ALND were recruited. Univariate and multivariate Logistic regression analysis was performed on variables related to NSLN metastasis. Results: According to the inclusion and exclusion criteria, a total of 495 cases were analyzed in univariate and multivariate analysis. The study revealed 174(35.2%) patients were with NSLN metastasis; ≥3positive SLN metastases(P<0.000), receptor status(P=0.007), and lymph-vascular invasion(P=0.006) were associated with NSLN metastases. Multivariate analysis revealed that ≥3 positive SLN metastases was the most important independent predictor for NSLN metastases(OR=6.604, 95%CI 3.451~12.638, P<0.000). For patients with different risk factors, the NSLN metastatic rates were 16.4%, 23.1%, 39.1%, and 60.7%, respectively. Conclusion: The number of positive NSLNs, receptor status, and lymph-vascular invasion were correlated with NSLN metastasis. The ≥3 positive SLNs may be an independent predictor for NSLN metastasis. When risk factors 2 or 3 are present, ALND is strongly recommended due to higher than ACOSOG Z0011 trial (27.3%).

参考文献/References:

[1] Carter C, Allen C, Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases[J]. Cancer, 1989, 63(1): 181
[2] van der Ploeg I M, Nieweg O E, van Rijk M C, et al. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature[J]. Eur J Surg Oncol, 2008, 34(12): 1277
[3] Houssami N, Ciatto S, Turner R M, et al. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla[J]. Ann Surg, 2011, 254(2): 243
[4] Dialani V, James D F, Slanetz P J. A practical approach to imaging the axilla [J]. Insights into imaging, 2015, 6(2): 217
[5] Giuliano A E, Ballman K V, Mccall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial [J]. Jama, 2017, 318(10): 918
[6] Chen J J, Huang N S, Xue J Y, et al. Surgical management for early-stage bilateral breast cancer patients in China[J]. PLoS One, 2015, 10(4): e0122692
[7] Qiu S Q, Zeng H C, Zhang F, et al. A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound[J]. Sci Rep, 2016, 6:21196
[8] Donker M, Van Tienhoven G, Straver M E, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12): 1303
[9] Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial[J]. Eur J Surg Oncol, 2017, 43(4): 672
[10] Galimberti V, Cole B F, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases(IBCSG 23-01): a phase 3 randomised controlled trial[J]. Lancet Oncol, 2013, 14(4): 297
[11] Canavese G, Bruzzi P, Catturich A, et al. A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes[J]. Eur J Surg Oncol, 2014, 40(7): 835
[12] Jinno H, Sakata M, Asaga S, et al. Predictors to assess non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis[J]. Breast J, 2008, 14(6): 551
[13] Maimaitiaili A, Wu D, Liu Z, et al. Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients[J]. Cancer Biol Med, 2018, 15(3): 282
[14] Chue K M, Yong W S, Thike A A, et al. Predicting the likelihood of additional lymph node metastasis in sentinel lymph node positive breast cancer: validation of the memorial sloan-kettering cancer centre (MSKCC) nomogram[J]. J Clin Pathol, 2014, 67(2): 112
[15] Bi X, Wang Y, Li M, et al. Validation of the memorial sloan kettering cancer center nomogram for predicting non-sentinel lymph node metastasis in sentinel lymph node-positive breast-cancer patients[J]. Onco Targets Ther, 2015, 8:487
[16] Bevilacqua J L, Kattan M W, Fey J V, et al. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation [J]. J Clin Oncol, 2007, 25(24): 3670
[17] van C B, vanden Bempt I, Drijkoningen M, et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive[J]. Breast Cancer Res Treat, 2009, 113(1): 181
[18] Gur A S, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy[J]. J Am Coll Surg, 2009, 208(2): 229
[19] Suyoi A, Bains S K, Kothari A, et al. When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node[J]. Eur J Cancer, 2014, 50(4): 690
[20] Degnim A C, Zakaria S, Boughey J C, et al. Axillary recurrence in breast cancer patients with isolated tumor cells in the sentinel lymph node [AJCC N0(i+)] [J]. Ann Surg Oncol, 2010, 17(10): 2685
[21] Sola M, Alberro J A, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000[J]. Ann Surg Oncol, 2013, 20(1): 120
[22] Goyal A, Dodwell D. POSNOC: A randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases [J]. Clin Oncol, 2015, 27(12): 692
[23] de Boniface J, Frisell J, Andersson Y, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial[J]. BMC Cancer, 2017, 17(1): 379
[24] Tinierri C, Canavese G, Bruzzi P, et al. SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes[J]. Breast, 2016, 30:197
[25] van Roozendaal L M, de Wilt J H, van Dalen T, et al. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a dutch randomized controlled multicentre trial (BOOG 2013-07)[J]. BMC Cancer, 2015, 15:610

相似文献/References:

[1]朱悦,张诗武,张丹芳,等.TA2小鼠自发乳腺癌血清蛋白质组学研究[J].天津医科大学学报,2013,19(05):373.
[2]刘 营,孙保存,刘铁菊,等.AURKA蛋白激酶在三阴乳腺癌干细胞形成血管拟态中的实验研究[J].天津医科大学学报,2013,19(06):437.
　LIU Ying,SUN Bao-cun,LIU Tie-ju,et al.Experimental study of AURKA protein kinase in the formation of vascular mimicry in triple-negative breast cancer stem cells[J].Journal of Tianjin Medical University,2013,19(04):437.
[3]伦淑敏.HOXA5基因真核表达质粒的构建及在乳腺癌细胞中的功能研究[J].天津医科大学学报,2014,20(05):337.
　LUN Shu-min. Construction of HOXA5 eukaryotic expression plasmid of and its biological significance in breast cancer cells[J].Journal of Tianjin Medical University,2014,20(04):337.
[4]伦淑敏.肌细胞增强因子2A基因真核表达质粒的构建及对乳腺癌细胞MCF-7增殖能力的影响[J].天津医科大学学报,2014,20(06):429.
　LUN Shu-min.Construction of myocyte enhancer factor 2A eukaryotic expression plasmid and effects on cell proliferation in breast cancer cell line MCF7[J].Journal of Tianjin Medical University,2014,20(04):429.
[5]孙秀梅,张 飞,田 然,等.Nanog表达上调促进乳腺癌细胞MCF-7的增殖和侵袭[J].天津医科大学学报,2014,20(06):421.
　SUN Xiu-mei,ZHANG Fei,TIAN Ran,et al.Up-regulation of Nanog promotes cell proliferation and invasion in breast cancer cells MCF-7[J].Journal of Tianjin Medical University,2014,20(04):421.
[6]张 洁,张 飞,冀 为,等. SHP2不同突变体对乳腺癌细胞的迁移和侵袭能力的影响[J].天津医科大学学报,2015,21(02):93.
　ZHANG Jie,ZHANG Fei,JI Wei,et al. Effect of different SHP2 mutants on breast cancer cell migration and invasion[J].Journal of Tianjin Medical University,2015,21(04):93.
[7]蔡 隽. FOXQ1稳定表达乳腺癌细胞系的建立及鉴定[J].天津医科大学学报,2015,21(04):292.
　CAI Jun.Establishment and identification of cell lines with stable expression of FOXQ1 in MDA-MB-231-luc[J].Journal of Tianjin Medical University,2015,21(04):292.
[8]蔡 隽 综述,冯玉梅 审校.叉头框转录因子调控乳腺癌生物学特性的研究进展[J].天津医科大学学报,2015,21(05):455.
[9]任宗娜.沉默Notch4基因对乳腺癌细胞系MDA-MB-231增殖和迁移侵袭能力的影响[J].天津医科大学学报,2015,21(06):469.
　REN Zong-na.Inhibition effect of?silencing?? Notch4 gene on the proliferation and migration and invasion activity of? breast cancer cell line?MDA-MB-231[J].Journal of Tianjin Medical University,2015,21(04):469.
[10]周岩,宋伟杰,张飞,等.人附睾蛋白4在乳腺癌发生发展中的机制研究[J].天津医科大学学报,2015,21(06):466.
　ZHOU Yan,SONG Wei-jie,ZHANG Fei,et al.Mechanism of human epididymis protein 4 in development and progression of breast cancer[J].Journal of Tianjin Medical University,2015,21(04):466.

备注/Memo

备注/Memo:

作者简介 王雪（1992-），女，硕士在读，研究方向：肿瘤学；通信作者：张斌，E-mail: eeflying@163.com。

常用功能

更新日期/Last Update: 2019-08-28